Table 1.

List of clinical trials on novel agents and combinatorial treatment for MDS.

Drug		Phase	Disease Subtype	Regimen	Status	Clinical Trial Identifier
Immune Checkpoint Inhibitors
Pembrolizumab	Anti-PD1	1	Hematologic malignancies	Pembrolizumab	Completed	NCT01953692
		1	MDS	Pembrolizumab + Entinostat	Active, not recruiting	NCT02936752
		2	MDS	Pembrolizumab + AZA	Recruiting	NCT03094637
		1	ND/RR AML/MDS	Pembrolizumab + DEC	Recruiting	NCT03969446
Nivolumab		2	MDS, R/R MDS	Nivolumab + AZA, Ipilimumab + AZA	Recruiting	NCT02530463
		2/3	AML, MDS	AZA + Nivolumab/Midostaurin, DEC + Cytarabine	Active, not recruiting	NCT03092674
Durvalumab (MEDI4736)	Anti-PD-L1	1	MDS	Durvalumab, Durvalumab + Tremelimumab	Completed	NCT02117219
		2	MDS	Durvalumab + AZA	Active, not recruiting	NCT02281084
		2	AML, MDS	AZA, AZA + Durvalumab	Active, not recruiting	NCT02775903
Ipilimumab	Anti-CTLA-4	1	R/R MDS, AML	Ipilimumab + DEC	Recruiting	NCT02890329
Sabatolimab (MBG453)	Anti-TIM-3	1	AML, HR-MDS	MBG453, or in combination with PDR001/DEC/AZA	Active, not recruiting	NCT03066648
		2	HR-MDS	MBG453 + HMA	Active, not recruiting	NCT03946670
		3	HR-MDS, CMML-2	MBG453 + AZA	Recruiting	NCT04266301
		2	HR-MDS	Sabatolimab + AZA + Venetoclax	Not yet recruiting	NCT04812548
		2	HR-MDS	Sabatolimab + AZA/DEC	Not yet recruiting	NCT04878432
TTI-621 (SIRPαFc)	Anti-CD47	1	Hematologic malignancies, solid tumors	TTI-621 for MDS	Recruiting	NCT02663518
Magrolimab		1	Hematologic malignancies	Magrolimab, Magrolimab + AZA	Recruiting	NCT03248479
		3	MDS	AZA, AZA + Magrolimab	Recruiting	NCT04313881
AK117		1/2	MDS	AK117 + AZA	Recruiting	NCT04900350

Abbreviations: ND, newly diagnosed.